Clinical Trial Update: A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial of Dato-DXd (datopotamab deruxtecan) is evaluating inoperable or metastatic hormone receptor-positive, HER2 IHC 0 breast cancer and is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING